作者
Mônica Samuel Avila, Silvia Moreira Ayub-Ferreira, Mauro Rogerio de Barros Wanderley, Fatima das Dores Cruz, Sara Michelly Goncalves Brandao, Vagner Oliveira Carvalho Rigaud, Marília Harumi Higuchi-dos-Santos, Ludhmila Abrahão Hajjar, Roberto Kalil Filho, Paulo Marcelo Hoff, Marina Sahade, Marcela SM Ferrari, Romulo Leopoldo de Paula Costa, Max Senna Mano, Cecilia Beatriz Bittencourt Viana Cruz, Maria Cristina Abduch, Marco Stephan Lofrano Alves, Guilherme Veiga Guimaraes, Victor Sarli Issa, Marcio Sommer Bittencourt, Edimar Alcides Bocchi
发表日期
2018/5/22
期刊
Journal of the American College of Cardiology
卷号
71
期号
20
页码范围
2281-2290
出版商
American College of Cardiology Foundation
简介
Background
Anthracycline (ANT) chemotherapy is associated with cardiotoxicity. Prevention with β-blockers remains controversial.
Objectives
This prospective, randomized, double-blind, placebo-controlled study sought to evaluate the role of carvedilol in preventing ANT cardiotoxicity.
Methods
The authors randomized 200 patients with HER2-negative breast cancer tumor status and normal left ventricular ejection fraction (LVEF) referred for ANT (240 mg/m2) to receive carvedilol or placebo until chemotherapy completion. The primary endpoint was prevention of a ≥10% reduction in LVEF at 6 months. Secondary outcomes were effects of carvedilol on troponin I, B-type natriuretic peptide, and diastolic dysfunction.
Results
Primary endpoint occurred in 14 patients (14.5%) in the carvedilol group and 13 patients (13.5%) in the placebo group (p = 1.0). No differences in changes of LVEF or B-type natriuretic peptide were …
学术搜索中的文章
MS Avila, SM Ayub-Ferreira, MR de Barros Wanderley… - Journal of the American College of Cardiology, 2018